Skip to main content
Toggle navigation
Login
Search
Home
Tweets by IDWeek 2022
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back
Favorite
Like
Tweet this
Print
Adam B. Shapiro, Ph.D
Research Fellow
Entasis Therapeutics
Disclosure(s): Entasis Therapeutics: Employee, Stocks/Bonds
Poster(s):
225 - Efficacy and safety of sulbactam-durlobactam are consistent across regions in the global ATTACK phase 3 trial in the treatment of carbapenem-resistant
Acinetobacter baumannii-calcoaceticus
complex (CRABC) infections
Thursday, October 20, 2022
12:15 PM – 1:30 PM
US ET